Effect of iGlarLixi on continuous glucose monitoring—measured time in range in insulin‐naive adults with suboptimally controlled type 2 diabetes
Authors' conclusion
In people with T2D suboptimally controlled on ≥2 OADs ± GLP-1 RAs, 16 weeks of treatment with iGlarLixi significantly improved TIR and reduced TAR without severe hypoglycaemia.
Study context
- Population
- Insulin-naive adults with T2D and HbA1c ≥9%-13% receiving ≥2 OADs ± GLP-1 RAs; mean age 55.6 years, HbA1c 10.2%enrolled
- Participants
- 124 adults
- Outcome
- Change from baseline in percent TIR (70-180 mg/dL)
- Follow-up
- Week 16
Methodological detailsmulticentre, open-label, blinded continuous glucose monitoring (CGM)
- Multicentre
- Open-label
- Blinded CGM
Main finding
As reported in the abstract
Change in TIR
Change in time in range (TIR) with iGlarLixi
+26.2%
Secondary outcomes
Change in mean daily blood glucose (BG) · week 16
- Change in mean BG with iGlarLixi
- −52.5 mg/dL
- p < 0.001
Change in maximum PPG 4 h post-breakfast · week 16
- Change in maximum PPG-4 h with iGlarLixi
- −73.7 mg/dL
- p < 0.001
Change in time above range (TAR) (>180 mg/dL) · week 16
- Change in TAR with iGlarLixi
- −28.7%
- p < 0.001
Safety
On-treatment hypoglycaemia (American Diabetes Association levels) · 16 weeks
- Level 1 hypoglycaemia (BG <70 but ≥54 mg/dL), events per person-year
- 1.4
- Level 2 hypoglycaemia (BG <54 mg/dL), events per person-year
- 0.6
- No level 3 events (requiring assistance) were reported
Original publication
Effect of iGlarLixi on continuous glucose monitoring—measured time in range in insulin‐naive adults with suboptimally controlled type 2 diabetes. Diabetes Obes Metab. Published 4 February 2025. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →